ClinicalTrials.gg
CompletedNCT04878731Updated Jul 7, 2023Results posted

Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia

A Phase 1 interventional study of PF-06741086 in Severe Hemophilia, sponsored by Pfizer. Completed at 1 site in China. Open to male participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2023-07-07.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 74 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 47 studies in Hemophilia A by Pfizer — 6 open to participants now, 9 under way, 6 of them phase 3. Hemophilia A · Pfizer.

Enrollment
29th of 32
6 · median 34
Started
2021
with 2 others
Phase 1
5 of 47
1 open now
Registered
39th of 47
by date

Among the 47 studies in Hemophilia A by Pfizer, this one is the 29th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2021, is one of 5 in phase 1, and was the 39th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

6 of the 47 studies in Hemophilia A by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 74 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Hemophilia A by Pfizer, or all of them as a file.
02

Study summary

This Phase 1 study will be a single-arm, open-label, non-randomized, non-controlled investigation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06741086 in Chinese adult participants with severe hemophilia.

03

Conditions studied

  • Severe Hemophilia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be male and 18 to \<75 years of age with a minimum body weight of 30 kg at screening.
  • Participants with a diagnosis of severe hemophilia A or B (FVIII or FIX activity \<1%, respectively)
  • Participants without inhibitor must also meet the following criteria:

    • No detectable or documented history of inhibitors
    • Participants with on-demand treatment regimen with ≥6 acute bleeding episodes (spontaneous or traumatic) that required coagulation factor infusion during the 4 months period prior to enrollment and willing to continue to receive on demand treatment during the study.
  • Participants with Inhibitor must also meet the following criteria:

    • Documentation of current high titer inhibitor (≥5 BU/mL) or current low titer inhibitor (\<5 BU/mL) to FVIII or FIX replacement and with FVIII or FIX recovery \<60% of expected within previous 4 months prior to screening.
    • Participants with on-demand treatment regimen with ≥6 bleeding episodes (spontaneous and/or traumatic) necessitating treatment with bypass factor for at least 4 months prior to screening and willing to continue to receive on-demand treatment during the study.

Exclusion criteria

Exclusion Criteria:

  • Previous or current treatment for and/or history of coronary artery diseases, venous or arterial thrombosis or ischemic disease
  • Known planned surgical procedure during the planned study period.
  • Known hemostatic defect other than hemophilia A or B.
  • Abnormal renal or hepatic function
  • Current unstable liver or biliary disease
  • Abnormal hematologic parameters
  • Abnormal coagulation activity
  • Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, in the judgment of the investigator.
  • interval (QTc) >450 msec for male participants or QTc >480 msec in participants with bundle branch block.
  • Individuals with or an allergic reaction to hamster protein or other components of the study intervention.
  • A positive urine drug screen
  • Current routine prophylaxis with bypassing agent or non coagulation factor-replacement therapy (eg, emicizumab)
  • Regular, concomitant therapy with immunomodulatory drugs
  • Ongoing or planned use of immune tolerance induction or prophylaxis with FVIII or FIX replacement during the study.
  • Participation in other studies involving investigational drug(s) within 30 days (or as determined by local requirements) or 5 half-lives prior to study entry and/or during study participation.
  • ≤200/uL if (HIV)-positive
  • Baseline that demonstrates abnormalities that may affect participant safety or interpretation of study results.
  • Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are Pfizer employees, including their family members, directly involved in the conduct of the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    single arm

    PF-06741086 300mg subcutaneous(SC)

    Biological: PF-06741086

Interventions

  • BiologicalPF-06741086

    single dose SC injection of 300 mg PF-06741086

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with study treatment. TEAEs=AEs that started during the effective duration of treatment regardless of whether a similar event existed at baseline. Grades of AEs were defined by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 5.0. Grade 1=asymptomatic/mild symptoms, clinical or diagnostic observations only, intervention not indicated;Grade 2=minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activity of daily living (ADL);Grade 3=severe or medically significant but not immediately life-threatening, hospitalization of prolongation of hospitalization indicated; disabling limiting self-care ADL;Grade 4=events with life-threatening consequences, urgent intervention indicated;Grade 5= death related to AE.Treatment-related TEAEs were determined by investigator.

    Time frame: Day 1 to Day 42

  2. Number of Participants With Serious Adverse Events (SAEs)

    An SAE was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect. Treatment-related SAEs were determined by the investigator.

    Time frame: Day 1 to Day 42

  3. Number of Participants With Maximum Grade 3 or 4 or 5 TEAEs

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with study treatment. TEAEs=AEs that started during the effective duration of treatment regardless of whether a similar event existed in the baseline period. Grades of AEs were defined by NCI CTCAE version 5.0. Grade 1=asymptomatic/mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2=minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activity of daily living (ADL); Grade 3=severe or medically significant but not immediately life-threatening, hospitalization of prolongation of hospitalization indicated; disabling limiting self-care ADL; Grade 4=events with life-threatening consequences, urgent intervention indicated; Grade 5= death related to AE. Treatment-related TEAEs were determined by the investigator.

    Time frame: Day 1 to Day 42

  4. Number of Participants With TEAEs Leading to Permanent or Temporary Discontinuation From Study

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with study treatment. TEAEs=AEs that started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period. Grades of AEs were defined by NCI CTCAE version 5.0. Grade 1=asymptomatic/mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2=minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activity of daily living (ADL); Grade 3=severe or medically significant but not immediately life-threatening, hospitalization of prolongation of hospitalization indicated; disabling limiting self-care ADL; Grade 4=events with life-threatening consequences, urgent intervention indicated; Grade 5= death related to AE. Treatment-related TEAEs were determined by the investigator.

    Time frame: Day 1 to Day 42

  5. Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality

    Laboratory assessments included chemistry, hematology, Prothrombin Time/International Normalized Ratio (PT/INR), Activated Partial Thromboplastin Time (APTT), urinalysis, fibrinogen, Antithrombin III (ATIII) activity, and Cardiac Troponin I (cTnI). Laboratory test abnormalities reported by at least 1 participant are reported in this outcome measure. ULN = upper limit of normal.

    Time frame: Day 1 to Day 28

  6. Mean Absolute Value of Prothrombin Time (PT) / International Normalized Ratio (INR)

    PT is one of the laboratory tests to evaluate the ability of blood clotting. The INR is derived from PT which is calculated as a ratio of a participant's PT to a control PT standardized for the potency of the thromboplastin reagent developed by the World Health Organization (WHO) using the following formula: INR = Participant PT / Control PT. Blood samples were obtained to evaluate PT/INR.

    Time frame: Day 1, Day 2, Day 7, Day 14, Day 21, Day 28

  7. Change From Baseline in PT/INR at Days 2, 7, 14, 21 and 28

    PT is one of the laboratory tests to evaluate the ability of blood clotting. The INR is derived from PT which is calculated as a ratio of a participant's PT to a control PT standardized for the potency of the thromboplastin reagent developed by the WHO using the following formula: INR = Participant PT / Control PT. Blood samples were obtained to evaluate PT/INR.

    Time frame: Baseline (Day 1), Day 2, Day 7, Day 14, Day 21, Day 28

  8. Mean Absolute Value of Activated Partial Thromboplastin Time (APTT)

    The APTT is a screening test that helps evaluate a person's ability to appropriately form blood clots. It measures the number of seconds it takes for a clot to form in a sample of blood after substances (reagents) are added. Blood samples were obtained to evaluate APTT.

    Time frame: Day 1, Day 2, Day 7, Day 14, Day 21, Day 28

  9. Change From Baseline in APTT at Days 2, 7, 14, 21 and 28

    The APTT is a screening test that helps evaluate a person's ability to appropriately form blood clots. It measures the number of seconds it takes for a clot to form in a sample of blood after substances (reagents) are added. Blood samples were obtained to evaluate APTT.

    Time frame: Baseline (Day 1), Day 2, Day 7, Day 14, Day 21, Day 28

  10. Mean Absolute Value of Fibrinogen

    Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. Blood samples were obtained to evaluate the amount of fibrinogen.

    Time frame: Day 1, Day 2, Day 7, Day 14, Day 21, Day 28

  11. Change From Baseline in Fibrinogen at Days 2, 7, 14, 21 and 28

    Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. Blood samples were obtained to evaluate the amount of fibrinogen.

    Time frame: Baseline (Day 1), Day 2, Day 7, Day 14, Day 21, Day 28

  12. Mean Absolute Value of Antithrombin III (ATIII)

    ATIII is a nonvitamin K-dependent protease that inhibits coagulation by lysing thrombin and factor Xa. The antithrombin activity test measures how well the protein inhibits thrombin, with a reference range of 75% - 125%. Blood samples were obtained to evaluate ATIII activity.

    Time frame: Day 1, Day 2, Day 7, Day 14, Day 21, Day 28

  13. Change From Baseline in ATIII at Days 2, 7, 14, 21 and 28

    ATIII is a nonvitamin K-dependent protease that inhibits coagulation by lysing thrombin and factor Xa. The antithrombin activity test measures how well the protein inhibits thrombin, with a reference range of 75% - 125%. Blood samples were obtained to evaluate ATIII activity.

    Time frame: Baseline (Day 1), Day 2, Day 7, Day 14, Day 21, Day 28

  14. Mean Absolute Value of Cardiac Troponin I (cTnI)

    cTnI is one of the cardiac regulatory proteins that control the calcium mediated interaction between actin and myosin, and is considered a specific marker for cardiac damage. Blood samples were obtained to evaluate the amount of cTnI.

    Time frame: Day 1, Day 2, Day 4

  15. Change From Baseline in cTnI at Days 2 and 4

    cTnI is one of the cardiac regulatory proteins that control the calcium mediated interaction between actin and myosin, and is considered a specific marker for cardiac damage. Blood samples were obtained to evaluate the amount of cTnI.

    Time frame: Baseline (Day 1), Day 2, Day 4

  16. Number of Participants With Vital Signs Data Meeting Categorical Criteria of Potential Clinical Concern

    Vital signs measurements included blood pressure (BP), pulse rate, respiratory rate and oral temperature. Categorical classes for vital signs of potential clinical concern included: (1) systolic BP - minimum (min) value \<90 mmHg, maximum (max) decrease/increase from baseline \>=30 mmHg; (2) diastolic BP - min value \<50 mmHg, max decrease/increase from baseline \>=20 mmHg; (3) supine pulse rate - min \<40 beat per minute (bpm) or max \>120 bpm; (4) standing pulse rate - min \<40 bpm or max \>140 bpm; (5) oral temperature \> 38.5 celsius degree (°C). BPs were measured in a supine position so standing BPs were not evaluated and not reported.

    Time frame: Day 1 to Day 28

  17. Change From Baseline in Supine Systolic BP at Days 1, 2, 3, 4, 7, 14, 21 and 28

    BPs were assessed in a supine position with a completely automated device. Categorical classes for supine systolic BP of potential clinical concern included min value \<90 mmHg, max decrease/increase from baseline \>=30 mmHg.

    Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.

  18. Change From Baseline in Diastolic Systolic BP at Days 1, 2, 3, 4, 7, 14, 21 and 28

    BPs were assessed in a supine position with a completely automated device. Categorical classes for supine diastolic BP of potential clinical concern included min value \<50 mmHg, max decrease/increase from baseline \>=20 mmHg.

    Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.

  19. Change From Baseline in Supine Pulse Rate at Days 1, 2, 3, 4, 7, 14, 21 and 28

    Pulse rates were assessed in a supine position with a completely automated device. Categorical classes for supine pulse rate of potential clinical concern included min value \<40 bpm or max value \>120 bpm.

    Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.

  20. Change From Baseline in Oral Temperature at Days 1, 2, 3, 4, 7, 14, 21 and 28

    No eating, drinking, or smoking was allowed for 15 minutes prior to the measurement of oral temperature. The criterion for oral temperature of potential clinical concern was oral temperature \> 38.5°C.

    Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.

  21. Change From Baseline in Respiratory Rate at Days 1, 2, 3, 4, 7, 14, 21 and 28

    Respiratory rate measurement was preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Respiratory rate was measured in terms of "breaths per minute", and was measured by observing and counting the respirations of the participant for 30 seconds and multiplied by 2.

    Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.

  22. Number of Participants With Electrocardiogram (ECG) Data Meeting Categorical Criteria of Potential Clinical Concern

    Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated heart rate and measured PR, QRS and QT intervals. If a single time point ECG was abnormal, a triplicate ECG was required and obtained approximately 2-4 minutes apart; the average of triplicate ECG measurements collected at pre-dose Day 1 served as each participant's baseline value. Categorical classes for ECG data of potential clinical concern included: (1) QTcF - 450 millisecond (msec)≤ max value \<480 msec, 480 msec ≤ max value \<500 msec, max value ≥500 msec; 30 msec ≤ QTcF max increase from baseline \<60 msec; max increase from baseline ≥60 msec; (2) PR interval - max value ≥300 msec, baseline value\>200 and max increase from baseline ≥25%, baseline value ≤200 and max increase from baseline ≥50%; (3) QRS interval - max value ≥140 msec, increase from baseline ≥50%.

    Time frame: Day 1 to Day 28

  23. Change From Baseline in ECG Mean Heart Rate at Days 1, 2, 3, 4, 7, 14, 21 and 28

    Heart rate was measured in terms of "beats per minute". Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. If a single time point ECG was abnormal, a triplicate ECG was required, which were obtained approximately 2-4 minutes apart; the average of the triplicate ECG measurements collected at pre-dose Day 1 served as each participant's baseline value.

    Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.

  24. Change From Baseline in PR Interval at Days 1, 2, 3, 4, 7, 14, 21 and 28

    Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. Categorical classes for PR interval data of potential clinical concern included: max value ≥300 ms, baseline value\>200 and max increase from baseline≥25%, baseline value ≤200 and max increase from baseline ≥50%.

    Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.

  25. Change From Baseline in QRS Interval at Days 1, 2, 3, 4, 7, 14, 21 and 28

    Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. Categorical classes for QRS interval data of potential clinical concern included: max value ≥140 ms, increase from baseline ≥50%.

    Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.

  26. Change From Baseline in QT Interval at Days 1, 2, 3, 4, 7, 14, 21 and 28

    Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals.

    Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.

  27. Change From Baseline in QT Interval Corrected at Days 1, 2, 3, 4, 7, 14, 21 and 28

    Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. The corrected QT interval (QTc) estimates the QT interval at a standard heart rate of 60 bpm.

    Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.

  28. Change From Baseline in Corrected QT Interval (Fridericia Method) (QTcF Interval) at Days 1, 2, 3, 4, 7, 14, 21 and 28

    Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. QTcF = QT interval corrected using the Fridericia method. Categorical classes for QTcF data of potential clinical concern included: 450 ms≤ max value \<480 ms, 480≤ max value \<500 ms, max value ≥500 ms; 30 ms ≤ QTcF max increase from baseline \<60 ms; max increase from baseline ≥60 ms.

    Time frame: Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.

  29. Number of Participants With Physical Examination Findings

    A complete PE included assessments of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. A brief PE included assessments of the general appearance, the respiratory and cardiovascular systems, as well as participant reported symptoms. The full PE planned for Screening may have been performed on Day -1 before dosing at the discretion of the Investigator. If a full PE was done at Screening visit, a brief PE was to be conducted on Day-1. After Day -1, brief examinations based on signs and symptoms may have been performed if clinically indicated at the discretion of the Investigator to assess changes from baseline/previous visits of any ongoing symptoms.

    Time frame: Screening (Day -35 to Day -2), Day -1, Day 1 (for general appearance, heart, lungs), Day 7 (for general appearance, heart, lungs), Day 28 (for general appearance, heart, lungs)

  30. Number of Participants With Injection Site Reactions

    Grades of injection site reactions were defined according to NCI CTCAE version 5.0. Grade 1=Tenderness with or without associated symptoms (eg, warmth, erythema, itching); Grade 2= Pain, lipodystrophy, edema, phlebitis; Grade 3= Ulceration or necrosis, severe tissue damage, operative intervention indicated; Grade 4=Life-threatening consequences, urgent intervention indicated; Grade 5=death. Participants with any grade of injection site reaction are reported in this outcome measure.

    Time frame: Day 1 to Day 7

Secondary outcomes

  1. Mean Plasma Marstacimab Concentration Versus Time at Days 1, 2, 3, 4, 7, 14, 21 and 28

    Mean plasma concentration of marstacimab after participants received a single SC injection of marstacimab 300 mg.

    Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing

  2. Maximum Plasma Concentration (Cmax) of Marstacimab

    Maximum plasma concentration of marstacimab after participants received a single SC injection of marstacimab 300 mg.

    Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing

  3. Time for Cmax (Tmax) of Marstacimab

    Time for Cmax of marstacimab after participants received a single SC injection of marstacimab 300 mg.

    Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing

  4. Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Marstacimab

    Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration of marstacimab after participants received a single SC injection of marstacimab 300 mg.

    Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing

  5. Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinity (AUCinf) of Marstacimab

    Area under the concentration time curve from time zero to infinity of marstacimab after participants received a single SC injection of marstacimab 300 mg.

    Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing

  6. Terminal Half-Life (t1/2) of Marstacimab

    Terminal half life (t1/2) of marstacimab after participants received a single SC injection of marstacimab 300 mg. t1/2 is defined as the time for plasma concentration to decrease by one half.

    Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing

  7. Apparent Volume of Distribution (Vz/F) of Marstacimab

    Apparent volume of distribution of marstacimab after participants received a single SC injection of marstacimab 300 mg. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was influenced by the fraction absorbed. Vz/F was calculated as dose/AUCinf. AUCinf = area under the concentration time curve from time zero to infinity.

    Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing

  8. Apparent Clearance (CL/F) of Marstacimab

    Apparent clearance (CL/F) of marstacimab after participants received a single SC injection of marstacimab 300 mg. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as Dose/ (AUCinf\*kel). AUCinf = area under the concentration time curve from time zero to infinity. kel = terminal phase rate constant calculated by a linear regression of the log linear concentration time curve.

    Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing

  9. Maximum Increase From Baseline for Tissue Factor Pathway Inhibitor (TFPI), Day 1 up to Day 28

    TFPI is a protease inhibitor, which acts as an antagonist of the extrinsic coagulation pathway via inhibition of tissue factor-activated coagulation factor VII (FVIIa) and activated factor X (FXa). Plasma total TFPI levels were measured to reflect target binding with marstacimab. TFPI in results represented total TFPI.

    Time frame: Day 1 to Day 28

  10. Area Under the Curve (AUC) of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for TFPI

    A change from baseline-time profile was established based on changes from baseline in TFPI at specific time points. Area under the TFPI change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure. TFPI represented total TFPI.

    Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing

  11. Maximum Increase From Baseline for Prothrombin Fragments 1+2 (PF 1+2), Day 1 up to Day 28

    PF1+2 is an in vivo endpoint reflective of coagulation pathway activation. Maximum increase from baseline for PF 1+2 was provided.

    Time frame: Day 1 to Day 28

  12. AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for PF 1+2

    A change from baseline-time profile was established based on changes from baseline in PF 1+2 at specific time points. Area under the PF 1+2 change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.

    Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing

  13. Maximum Increase From Baseline for D-Dimer, Day 1 up to Day 28

    D-dimer is an in vivo endpoint reflective of coagulation pathway activation. Maximum increase from baseline for D-Dimer is provided.

    Time frame: Day 1 to Day 28

  14. AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for D-Dimer

    A change from baseline-time profile was established based on changes from baseline in D-dimer at specific time points. Area under the D-dimer change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.

    Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing

  15. Maximum Decrease From Baseline for Dilute Prothrombin Time (dPT), Day 1 up to Day 28

    The dilute prothrombin time (dPT) is an ex vivo endpoint reflective of coagulation pathway activation. Maximum decrease from baseline for dPT is provided.

    Time frame: Day 1 to Day 28

  16. AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for dPT

    A change from baseline-time profile was established based on changes from baseline in dPT at specific time points. Area under the dPT change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.

    Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing

  17. Maximum Decrease From Baseline for Thrombin Generation Assay (TGA) Lag Time, Day 1 up to Day 28

    TGA lag time is an ex vivo endpoint reflective of coagulation pathway activation. Maximum decrease from baseline for TGA Lag Time is provided.

    Time frame: Day 1 to Day 28

  18. AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for TGA Lag Time

    A change from baseline-time profile was established based on changes from baseline in TGA lag time at specific time points. Area under the TGA lag time change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.

    Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing

  19. Maximum Increase From Baseline for TGA Peak, Day 1 up to Day 28

    TGA peak is an ex vivo endpoint reflective of coagulation pathway activation. Maximum increase from baseline for TGA Peak is provided.

    Time frame: Day 1 to Day 28

  20. AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for TGA Peak

    A change from baseline-time profile was established based on changes from baseline in TGA peak at specific time points. Area under the TGA peak change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.

    Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing

  21. Maximum Increase From Baseline for TGA Endogenous Thrombin Potential (EGTP), Day 1 up to Day 28

    TGA EGTP is an ex vivo endpoint reflective of coagulation pathway activation. Maximum increase from baseline for TGA Endogenous Thrombin Potential is provided.

    Time frame: Day 1 to Day 28

  22. AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for TGA EGTP

    A change from baseline-time profile was established based on changes from baseline in TGA EGTP at specific time points. Area under the TGA EGTP change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.

    Time frame: Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing

  23. Number of Participants With Anti-Drug Antibody (ADA) Against Marstacimab

    Summary of ADA incidence by visit is presented. ADA positive was defined as titer \>=1.54.

    Time frame: Day 1 pre-dose (-2 hours to -5 min prior to dosing); Day 14; Day 21; Day 28

  24. Number of Participants With Neutralizing Antibody (NAb) Against Marstacimab

    Summary of NAb incidence by visit is presented. NAb positive was defined as titer \>=1.08. ADA-positive participants (defined as titer \>=1.54) were analyzed for NAb.

    Time frame: Day 1 pre-dose (-2 hours to -5 min prior to dosing); Day 14; Day 21; Day 28

07

Results

Posted Jul 7, 2023

Participant flow

Participant flow — Overall Study
MilestonePF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Started6
Completed6
Not completed0

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with study treatment. TEAEs=AEs that started during the effective duration of treatment regardless of whether a similar event existed at baseline. Grades of AEs were defined by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 5.0. Grade 1=asymptomatic/mild symptoms, clinical or diagnostic observations only, intervention not indicated;Grade 2=minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activity of daily living (ADL);Grade 3=severe or medically significant but not immediately life-threatening, hospitalization of prolongation of hospitalization indicated; disabling limiting self-care ADL;Grade 4=events with life-threatening consequences, urgent intervention indicated;Grade 5= death related to AE.Treatment-related TEAEs were determined by investigator.

Time frame:
Day 1 to Day 42
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
All-Causality TEAEs1
Treatment-Related TEAEs0
All-Causality Severe TEAEs0
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

An SAE was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect. Treatment-related SAEs were determined by the investigator.

Time frame:
Day 1 to Day 42
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Number of Participants With Serious Adverse Events (SAEs)0
PrimaryNumber of Participants With Maximum Grade 3 or 4 or 5 TEAEs

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with study treatment. TEAEs=AEs that started during the effective duration of treatment regardless of whether a similar event existed in the baseline period. Grades of AEs were defined by NCI CTCAE version 5.0. Grade 1=asymptomatic/mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2=minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activity of daily living (ADL); Grade 3=severe or medically significant but not immediately life-threatening, hospitalization of prolongation of hospitalization indicated; disabling limiting self-care ADL; Grade 4=events with life-threatening consequences, urgent intervention indicated; Grade 5= death related to AE. Treatment-related TEAEs were determined by the investigator.

Time frame:
Day 1 to Day 42
Reported as:
Count of participants · Participants
Number of Participants With Maximum Grade 3 or 4 or 5 TEAEs
ParticipantsPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Number of Participants With Maximum Grade 3 or 4 or 5 TEAEs0
PrimaryNumber of Participants With TEAEs Leading to Permanent or Temporary Discontinuation From Study

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with study treatment. TEAEs=AEs that started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period. Grades of AEs were defined by NCI CTCAE version 5.0. Grade 1=asymptomatic/mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2=minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activity of daily living (ADL); Grade 3=severe or medically significant but not immediately life-threatening, hospitalization of prolongation of hospitalization indicated; disabling limiting self-care ADL; Grade 4=events with life-threatening consequences, urgent intervention indicated; Grade 5= death related to AE. Treatment-related TEAEs were determined by the investigator.

Time frame:
Day 1 to Day 42
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Permanent or Temporary Discontinuation From Study
ParticipantsPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Number of Participants With TEAEs Leading to Permanent or Temporary Discontinuation From Study0
PrimaryNumber of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality

Laboratory assessments included chemistry, hematology, Prothrombin Time/International Normalized Ratio (PT/INR), Activated Partial Thromboplastin Time (APTT), urinalysis, fibrinogen, Antithrombin III (ATIII) activity, and Cardiac Troponin I (cTnI). Laboratory test abnormalities reported by at least 1 participant are reported in this outcome measure. ULN = upper limit of normal.

Time frame:
Day 1 to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality
ParticipantsPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
APTT >1.1 x ULN6
Urine hemoglobin >=11
Urobilinogen >=12
PrimaryMean Absolute Value of Prothrombin Time (PT) / International Normalized Ratio (INR)

PT is one of the laboratory tests to evaluate the ability of blood clotting. The INR is derived from PT which is calculated as a ratio of a participant's PT to a control PT standardized for the potency of the thromboplastin reagent developed by the World Health Organization (WHO) using the following formula: INR = Participant PT / Control PT. Blood samples were obtained to evaluate PT/INR.

Time frame:
Day 1, Day 2, Day 7, Day 14, Day 21, Day 28
Reported as:
Mean · ratio
Mean Absolute Value of Prothrombin Time (PT) / International Normalized Ratio (INR)
ratioPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Day 11.000 ± 0.0790
Day 20.990 ± 0.0632
Day 70.972 ± 0.0549
Day 140.960 ± 0.0690
Day 210.982 ± 0.0902
Day 280.988 ± 0.0920
PrimaryChange From Baseline in PT/INR at Days 2, 7, 14, 21 and 28

PT is one of the laboratory tests to evaluate the ability of blood clotting. The INR is derived from PT which is calculated as a ratio of a participant's PT to a control PT standardized for the potency of the thromboplastin reagent developed by the WHO using the following formula: INR = Participant PT / Control PT. Blood samples were obtained to evaluate PT/INR.

Time frame:
Baseline (Day 1), Day 2, Day 7, Day 14, Day 21, Day 28
Reported as:
Mean · Ratio
Change From Baseline in PT/INR at Days 2, 7, 14, 21 and 28
RatioPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Day 2-0.010 ± 0.0363
Day 7-0.028 ± 0.0611
Day 14-0.040 ± 0.0379
Day 21-0.018 ± 0.0492
Day 28-0.012 ± 0.0741
PrimaryMean Absolute Value of Activated Partial Thromboplastin Time (APTT)

The APTT is a screening test that helps evaluate a person's ability to appropriately form blood clots. It measures the number of seconds it takes for a clot to form in a sample of blood after substances (reagents) are added. Blood samples were obtained to evaluate APTT.

Time frame:
Day 1, Day 2, Day 7, Day 14, Day 21, Day 28
Reported as:
Mean · second
Mean Absolute Value of Activated Partial Thromboplastin Time (APTT)
secondPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Day 185.38 ± 14.377
Day 287.15 ± 15.473
Day 787.78 ± 14.376
Day 1480.95 ± 17.521
Day 2164.10 ± 21.833
Day 2868.92 ± 16.144
PrimaryChange From Baseline in APTT at Days 2, 7, 14, 21 and 28

The APTT is a screening test that helps evaluate a person's ability to appropriately form blood clots. It measures the number of seconds it takes for a clot to form in a sample of blood after substances (reagents) are added. Blood samples were obtained to evaluate APTT.

Time frame:
Baseline (Day 1), Day 2, Day 7, Day 14, Day 21, Day 28
Reported as:
Mean · Second
Change From Baseline in APTT at Days 2, 7, 14, 21 and 28
SecondPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Day 21.77 ± 6.431
Day 72.40 ± 7.294
Day 14-4.43 ± 16.987
Day 21-21.28 ± 16.632
Day 28-16.47 ± 13.733
PrimaryMean Absolute Value of Fibrinogen

Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. Blood samples were obtained to evaluate the amount of fibrinogen.

Time frame:
Day 1, Day 2, Day 7, Day 14, Day 21, Day 28
Reported as:
Mean · milligram per deciliter (mg/dL)
Mean Absolute Value of Fibrinogen
milligram per deciliter (mg/dL)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Day 1284.3 ± 61.68
Day 2267.0 ± 52.37
Day 7249.5 ± 72.82
Day 14284.0 ± 50.12
Day 21267.7 ± 30.18
Day 28273.2 ± 43.73
PrimaryChange From Baseline in Fibrinogen at Days 2, 7, 14, 21 and 28

Fibrinogen is a protein, specifically a clotting factor (factor I), that is essential for proper blood clot formation. Blood samples were obtained to evaluate the amount of fibrinogen.

Time frame:
Baseline (Day 1), Day 2, Day 7, Day 14, Day 21, Day 28
Reported as:
Mean · mg/dL
Change From Baseline in Fibrinogen at Days 2, 7, 14, 21 and 28
mg/dLPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Day 2-17.3 ± 26.82
Day 7-34.8 ± 27.02
Day 14-0.3 ± 39.73
Day 21-16.7 ± 39.33
Day 28-11.2 ± 74.66
PrimaryMean Absolute Value of Antithrombin III (ATIII)

ATIII is a nonvitamin K-dependent protease that inhibits coagulation by lysing thrombin and factor Xa. The antithrombin activity test measures how well the protein inhibits thrombin, with a reference range of 75% - 125%. Blood samples were obtained to evaluate ATIII activity.

Time frame:
Day 1, Day 2, Day 7, Day 14, Day 21, Day 28
Reported as:
Mean · percent of antithrombin III activity
Mean Absolute Value of Antithrombin III (ATIII)
percent of antithrombin III activityPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Day 192.75 ± 6.498
Day 288.68 ± 3.939
Day 794.07 ± 4.384
Day 1497.98 ± 6.386
Day 2196.10 ± 3.949
Day 2897.18 ± 7.885
PrimaryChange From Baseline in ATIII at Days 2, 7, 14, 21 and 28

ATIII is a nonvitamin K-dependent protease that inhibits coagulation by lysing thrombin and factor Xa. The antithrombin activity test measures how well the protein inhibits thrombin, with a reference range of 75% - 125%. Blood samples were obtained to evaluate ATIII activity.

Time frame:
Baseline (Day 1), Day 2, Day 7, Day 14, Day 21, Day 28
Reported as:
Mean · percent of antithrombin III activity
Change From Baseline in ATIII at Days 2, 7, 14, 21 and 28
percent of antithrombin III activityPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Day 2-4.07 ± 4.399
Day 71.32 ± 5.739
Day 145.23 ± 7.655
Day 213.35 ± 5.899
Day 284.43 ± 6.207
PrimaryMean Absolute Value of Cardiac Troponin I (cTnI)

cTnI is one of the cardiac regulatory proteins that control the calcium mediated interaction between actin and myosin, and is considered a specific marker for cardiac damage. Blood samples were obtained to evaluate the amount of cTnI.

Time frame:
Day 1, Day 2, Day 4
Reported as:
Mean · nanogram per milliliter (ng/mL)
Mean Absolute Value of Cardiac Troponin I (cTnI)
nanogram per milliliter (ng/mL)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Day 10.0250 ± 0.00000
Day 20.0250 ± 0.00000
Day 40.0250 ± 0.00000
PrimaryChange From Baseline in cTnI at Days 2 and 4

cTnI is one of the cardiac regulatory proteins that control the calcium mediated interaction between actin and myosin, and is considered a specific marker for cardiac damage. Blood samples were obtained to evaluate the amount of cTnI.

Time frame:
Baseline (Day 1), Day 2, Day 4
Reported as:
Mean · ng/mL
Change From Baseline in cTnI at Days 2 and 4
ng/mLPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Day 20.0000 ± 0.0000
Day 40.0000 ± 0.00000
PrimaryNumber of Participants With Vital Signs Data Meeting Categorical Criteria of Potential Clinical Concern

Vital signs measurements included blood pressure (BP), pulse rate, respiratory rate and oral temperature. Categorical classes for vital signs of potential clinical concern included: (1) systolic BP - minimum (min) value \<90 mmHg, maximum (max) decrease/increase from baseline \>=30 mmHg; (2) diastolic BP - min value \<50 mmHg, max decrease/increase from baseline \>=20 mmHg; (3) supine pulse rate - min \<40 beat per minute (bpm) or max \>120 bpm; (4) standing pulse rate - min \<40 bpm or max \>140 bpm; (5) oral temperature \> 38.5 celsius degree (°C). BPs were measured in a supine position so standing BPs were not evaluated and not reported.

Time frame:
Day 1 to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Data Meeting Categorical Criteria of Potential Clinical Concern
ParticipantsPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Supine systolic BP value <90 mmHg0
Supine systolic BP increase from baseline >=30 mmHg0
Supine systolic BP decrease from baseline >=30 mmHg0
Supine diastolic BP value <50 mmHg0
Supine diastolic BP increase from baseline >=20 mmHg1
Supine diastolic BP decrease from baseline >=20 mmHg0
Supine pulse rate value <40 bpm0
Supine pulse rate value >120 bpm0
Body temperature >38.5 °C0
PrimaryChange From Baseline in Supine Systolic BP at Days 1, 2, 3, 4, 7, 14, 21 and 28

BPs were assessed in a supine position with a completely automated device. Categorical classes for supine systolic BP of potential clinical concern included min value \<90 mmHg, max decrease/increase from baseline \>=30 mmHg.

Time frame:
Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Reported as:
Mean · mmHg
Change From Baseline in Supine Systolic BP at Days 1, 2, 3, 4, 7, 14, 21 and 28
mmHgPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
1 hour post Day 1 dosing2.50 ± 9.503
2 hours post Day 1 dosing1.67 ± 8.189
4 hours post Day 1 dosing4.17 ± 8.519
8 hours post Day 1 dosing-1.83 ± 5.981
12 hours post Day 1 dosing3.00 ± 9.274
Day 2-0.67 ± 6.346
Day 30.17 ± 8.183
Day 42.17 ± 4.446
Day 71.67 ± 10.053
Day 144.00 ± 7.563
Day 211.00 ± 8.854
Day 28-0.50 ± 13.019
PrimaryChange From Baseline in Diastolic Systolic BP at Days 1, 2, 3, 4, 7, 14, 21 and 28

BPs were assessed in a supine position with a completely automated device. Categorical classes for supine diastolic BP of potential clinical concern included min value \<50 mmHg, max decrease/increase from baseline \>=20 mmHg.

Time frame:
Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Systolic BP at Days 1, 2, 3, 4, 7, 14, 21 and 28
mmHgPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
1 hour post Day 1 dosing-2.67 ± 7.659
2 hours post Day 1 dosing-3.83 ± 7.910
4 hours post Day 1 dosing-6.33 ± 7.146
8 hours post Day 1 dosing-8.67 ± 6.653
12 hours post Day 1 dosing-3.50 ± 8.597
Day 2-5.17 ± 6.145
Day 3-4.83 ± 8.085
Day 4-5.17 ± 6.145
Day 7-4.17 ± 9.087
Day 145.83 ± 9.475
Day 21-1.50 ± 8.118
Day 28-0.33 ± 6.218
PrimaryChange From Baseline in Supine Pulse Rate at Days 1, 2, 3, 4, 7, 14, 21 and 28

Pulse rates were assessed in a supine position with a completely automated device. Categorical classes for supine pulse rate of potential clinical concern included min value \<40 bpm or max value \>120 bpm.

Time frame:
Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Reported as:
Mean · bpm
Change From Baseline in Supine Pulse Rate at Days 1, 2, 3, 4, 7, 14, 21 and 28
bpmPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
1 hour post Day 1 dosing-1.33 ± 3.011
2 hours post Day 1 dosing-2.00 ± 3.521
4 hours post Day 1 dosing0.33 ± 11.003
8 hours post Day 1 dosing-1.50 ± 11.537
12 hours post Day 1 dosing-5.33 ± 6.501
Day 2-6.67 ± 8.937
Day 3-7.33 ± 6.683
Day 4-4.33 ± 11.361
Day 70.17 ± 15.198
Day 1414.33 ± 12.209
Day 2115.50 ± 13.882
Day 2810.50 ± 12.740
PrimaryChange From Baseline in Oral Temperature at Days 1, 2, 3, 4, 7, 14, 21 and 28

No eating, drinking, or smoking was allowed for 15 minutes prior to the measurement of oral temperature. The criterion for oral temperature of potential clinical concern was oral temperature \> 38.5°C.

Time frame:
Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Reported as:
Mean · degree Celsius
Change From Baseline in Oral Temperature at Days 1, 2, 3, 4, 7, 14, 21 and 28
degree CelsiusPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
1 hour post Day 1 dosing0.10 ± 0.502
2 hours post Day 1 dosing0.28 ± 0.621
4 hours post Day 1 dosing0.50 ± 0.827
8 hours post Day 1 dosing0.17 ± 0.501
12 hours post Day 1 dosing0.22 ± 0.581
Day 20.25 ± 0.582
Day 30.10 ± 0.566
Day 4-0.08 ± 0.523
Day 70.30 ± 0.626
Day 140.45 ± 0.701
Day 210.67 ± 0.700
Day 280.75 ± 0.579
PrimaryChange From Baseline in Respiratory Rate at Days 1, 2, 3, 4, 7, 14, 21 and 28

Respiratory rate measurement was preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Respiratory rate was measured in terms of "breaths per minute", and was measured by observing and counting the respirations of the participant for 30 seconds and multiplied by 2.

Time frame:
Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Reported as:
Mean · breaths per minute
Change From Baseline in Respiratory Rate at Days 1, 2, 3, 4, 7, 14, 21 and 28
breaths per minutePF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
1 hour post Day 1 dosing-0.50 ± 1.049
2 hours post Day 1 dosing-0.67 ± 1.033
4 hours post Day 1 dosing0.17 ± 2.994
8 hours post Day 1 dosing-0.50 ± 3.209
12 hours post Day 1 dosing-1.50 ± 1.975
Day 2-1.33 ± 1.506
Day 3-1.67 ± 1.751
Day 4-1.67 ± 3.502
Day 71.00 ± 4.980
Day 143.50 ± 2.811
Day 213.83 ± 3.312
Day 282.67 ± 3.141
PrimaryNumber of Participants With Electrocardiogram (ECG) Data Meeting Categorical Criteria of Potential Clinical Concern

Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated heart rate and measured PR, QRS and QT intervals. If a single time point ECG was abnormal, a triplicate ECG was required and obtained approximately 2-4 minutes apart; the average of triplicate ECG measurements collected at pre-dose Day 1 served as each participant's baseline value. Categorical classes for ECG data of potential clinical concern included: (1) QTcF - 450 millisecond (msec)≤ max value \<480 msec, 480 msec ≤ max value \<500 msec, max value ≥500 msec; 30 msec ≤ QTcF max increase from baseline \<60 msec; max increase from baseline ≥60 msec; (2) PR interval - max value ≥300 msec, baseline value\>200 and max increase from baseline ≥25%, baseline value ≤200 and max increase from baseline ≥50%; (3) QRS interval - max value ≥140 msec, increase from baseline ≥50%.

Time frame:
Day 1 to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Data Meeting Categorical Criteria of Potential Clinical Concern
ParticipantsPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
PR Interval Value >=300 msec0
PR Interval >=25% increase when baseline PR>200 msec, >=50% increase when baseline PR <=200 msec0
QRS Interval value >=140 msec0
QRS Interval % change from baseline >=50%0
QT Interval value >500 msec0
QTcF Interval value >= 450 msec and <480 msec0
QTcF Interval value >= 480 msec and <500 msec0
QTcF Interval value >= 500 msec0
QTcF Interval change from baseline >=30 msec and <60 msec0
QTcF Interval change from baseline >=60 msec0
PrimaryChange From Baseline in ECG Mean Heart Rate at Days 1, 2, 3, 4, 7, 14, 21 and 28

Heart rate was measured in terms of "beats per minute". Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. If a single time point ECG was abnormal, a triplicate ECG was required, which were obtained approximately 2-4 minutes apart; the average of the triplicate ECG measurements collected at pre-dose Day 1 served as each participant's baseline value.

Time frame:
Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Reported as:
Mean · beats per minute
Change From Baseline in ECG Mean Heart Rate at Days 1, 2, 3, 4, 7, 14, 21 and 28
beats per minutePF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
1 hour post Day 1 dosing0.43 ± 8.514
2 hours post Day 1 dosing-1.57 ± 8.105
4 hours post Day 1 dosing1.43 ± 14.581
8 hours post Day 1 dosing-1.73 ± 8.899
12 hours post Day 1 dosing-1.57 ± 4.670
Day 2-3.07 ± 9.917
Day 3-3.90 ± 11.858
Day 4-5.73 ± 10.560
Day 70.60 ± 17.580
Day 149.43 ± 10.869
Day 213.60 ± 5.953
Day 284.43 ± 10.872
PrimaryChange From Baseline in PR Interval at Days 1, 2, 3, 4, 7, 14, 21 and 28

Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. Categorical classes for PR interval data of potential clinical concern included: max value ≥300 ms, baseline value\>200 and max increase from baseline≥25%, baseline value ≤200 and max increase from baseline ≥50%.

Time frame:
Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Reported as:
Mean · millisecond
Change From Baseline in PR Interval at Days 1, 2, 3, 4, 7, 14, 21 and 28
millisecondPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
1 hour post Day 1 dosing-4.22 ± 12.490
2 hours post Day 1 dosing0.45 ± 33.789
4 hours post Day 1 dosing-8.38 ± 20.696
8 hours post Day 1 dosing-6.55 ± 9.592
12 hours post Day 1 dosing-10.88 ± 8.697
Day 2-2.72 ± 7.236
Day 3-6.05 ± 11.031
Day 4-4.55 ± 8.547
Day 7-6.22 ± 19.135
Day 14-10.22 ± 12.921
Day 21-8.05 ± 13.602
Day 28-4.05 ± 23.210
PrimaryChange From Baseline in QRS Interval at Days 1, 2, 3, 4, 7, 14, 21 and 28

Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. Categorical classes for QRS interval data of potential clinical concern included: max value ≥140 ms, increase from baseline ≥50%.

Time frame:
Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Reported as:
Mean · millisecond
Change From Baseline in QRS Interval at Days 1, 2, 3, 4, 7, 14, 21 and 28
millisecondPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
1 hour post Day 1 dosing-2.27 ± 4.698
2 hours post Day 1 dosing-4.27 ± 6.953
4 hours post Day 1 dosing-2.27 ± 5.972
8 hours post Day 1 dosing-1.60 ± 4.459
12 hours post Day 1 dosing1.57 ± 5.315
Day 2-2.77 ± 7.640
Day 3-2.60 ± 5.713
Day 4-4.10 ± 5.968
Day 7-0.43 ± 4.855
Day 14-5.10 ± 5.312
Day 21-4.60 ± 5.646
Day 28-4.60 ± 7.505
PrimaryChange From Baseline in QT Interval at Days 1, 2, 3, 4, 7, 14, 21 and 28

Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals.

Time frame:
Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Reported as:
Mean · millisecond
Change From Baseline in QT Interval at Days 1, 2, 3, 4, 7, 14, 21 and 28
millisecondPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
1 hour post Day 1 dosing-6.57 ± 14.714
2 hours post Day 1 dosing-0.90 ± 16.160
4 hours post Day 1 dosing-11.07 ± 24.048
8 hours post Day 1 dosing-0.07 ± 21.771
12 hours post Day 1 dosing2.60 ± 8.630
Day 20.77 ± 20.963
Day 30.60 ± 17.506
Day 4-0.07 ± 28.348
Day 7-5.90 ± 29.938
Day 14-30.40 ± 21.731
Day 21-17.57 ± 18.007
Day 28-19.07 ± 23.601
PrimaryChange From Baseline in QT Interval Corrected at Days 1, 2, 3, 4, 7, 14, 21 and 28

Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. The corrected QT interval (QTc) estimates the QT interval at a standard heart rate of 60 bpm.

Time frame:
Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Reported as:
Mean · millisecond
Change From Baseline in QT Interval Corrected at Days 1, 2, 3, 4, 7, 14, 21 and 28
millisecondPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
1 hour post Day 1 dosing-4.15 ± 14.416
2 hours post Day 1 dosing-4.82 ± 11.811
4 hours post Day 1 dosing-7.15 ± 22.601
8 hours post Day 1 dosing-4.15 ± 11.556
12 hours post Day 1 dosing-0.32 ± 11.397
Day 2-7.82 ± 16.104
Day 3-11.65 ± 17.928
Day 4-16.82 ± 8.169
Day 7-4.98 ± 22.013
Day 14-8.48 ± 15.359
Day 21-8.98 ± 12.716
Day 28-8.65 ± 11.854
PrimaryChange From Baseline in Corrected QT Interval (Fridericia Method) (QTcF Interval) at Days 1, 2, 3, 4, 7, 14, 21 and 28

Single 12-lead ECGs were performed for all participants in a supine position using an ECG machine that automatically calculated the heart rate and measured PR, QRS, and QT intervals. QTcF = QT interval corrected using the Fridericia method. Categorical classes for QTcF data of potential clinical concern included: 450 ms≤ max value \<480 ms, 480≤ max value \<500 ms, max value ≥500 ms; 30 ms ≤ QTcF max increase from baseline \<60 ms; max increase from baseline ≥60 ms.

Time frame:
Day 1 pre-dose (baseline); 1 hour, 2 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing; Day 2; Day 3; Day 4; Day 7; Day 14; Day 21; Day 28.
Reported as:
Mean · millisecond
Change From Baseline in Corrected QT Interval (Fridericia Method) (QTcF Interval) at Days 1, 2, 3, 4, 7, 14, 21 and 28
millisecondPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
1 hour post Day 1 dosing-5.38 ± 8.692
2 hours post Day 1 dosing-3.22 ± 7.499
4 hours post Day 1 dosing-8.55 ± 12.561
8 hours post Day 1 dosing-2.88 ± 10.471
12 hours post Day 1 dosing0.28 ± 8.084
Day 2-4.88 ± 12.496
Day 3-7.05 ± 7.900
Day 4-10.88 ± 11.337
Day 7-5.55 ± 9.932
Day 14-15.22 ± 11.354
Day 21-11.05 ± 12.049
Day 28-11.38 ± 9.550
PrimaryNumber of Participants With Physical Examination Findings

A complete PE included assessments of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. A brief PE included assessments of the general appearance, the respiratory and cardiovascular systems, as well as participant reported symptoms. The full PE planned for Screening may have been performed on Day -1 before dosing at the discretion of the Investigator. If a full PE was done at Screening visit, a brief PE was to be conducted on Day-1. After Day -1, brief examinations based on signs and symptoms may have been performed if clinically indicated at the discretion of the Investigator to assess changes from baseline/previous visits of any ongoing symptoms.

Time frame:
Screening (Day -35 to Day -2), Day -1, Day 1 (for general appearance, heart, lungs), Day 7 (for general appearance, heart, lungs), Day 28 (for general appearance, heart, lungs)
Reported as:
Count of participants · Participants
Number of Participants With Physical Examination Findings
ParticipantsPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Ears at screening0
Ears on Day -10
Eyes at screening0
Eyes on Day -10
Gastrointestinal at screening0
Gastrointestinal on Day -10
General appearance at screening0
General appearance on Day -10
General appearance on Day 10
General appearance on Day 70
General appearance on Day 280
Head at screening0
Head on Day -10
Heart at screening0
Heart on Day -10
Heart on Day 10
Heart on Day 70
Heart on Day 280
Lungs at screening0
Lungs on Day -10
Lungs on Day 10
Lungs on Day 70
Lungs on Day 280
Lymph nodes at screening0
Lymph nodes on Day -10
Mouth at screening0
Mouth on Day -10
Musculoskeletal system at screening6
Musculoskeletal system on Day -16
Neurological system at screening0
Neurological system on Day -10
Nose at screening0
Nose on Day -10
Skin at screening0
Skin on Day -10
PrimaryNumber of Participants With Injection Site Reactions

Grades of injection site reactions were defined according to NCI CTCAE version 5.0. Grade 1=Tenderness with or without associated symptoms (eg, warmth, erythema, itching); Grade 2= Pain, lipodystrophy, edema, phlebitis; Grade 3= Ulceration or necrosis, severe tissue damage, operative intervention indicated; Grade 4=Life-threatening consequences, urgent intervention indicated; Grade 5=death. Participants with any grade of injection site reaction are reported in this outcome measure.

Time frame:
Day 1 to Day 7
Reported as:
Count of participants · Participants
Number of Participants With Injection Site Reactions
ParticipantsPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Number of Participants With Injection Site Reactions0
SecondaryMean Plasma Marstacimab Concentration Versus Time at Days 1, 2, 3, 4, 7, 14, 21 and 28

Mean plasma concentration of marstacimab after participants received a single SC injection of marstacimab 300 mg.

Time frame:
Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Reported as:
Mean · ng/mL
Mean Plasma Marstacimab Concentration Versus Time at Days 1, 2, 3, 4, 7, 14, 21 and 28
ng/mLPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Day 1 pre-dose0.0000 ± 0.0000
1 hour post Day 1 dosing582.0 ± 1313.2
4 hours post Day 1 dosing1746 ± 960.3
12 hours post Day 1 dosing5647 ± 2254.2
Day 2, 24 hours post Day 1 dosing9033 ± 3349.8
Day 3, 48 hours post Day 1 dosing14300 ± 5510.3
Day 4, 72 hours post Day 1 dosing16060 ± 5706.9
Day 7, approximately 144 hours post Day 1 dosing14600 ± 4693.9
Day 14, approximately 312 hours post Day 1 dosing3437 ± 2349.3
Day 21, approximately 480 hours post Day 1 dosing53.17 ± 130.23
Day 28, approximately 648 hours post Day 1 dosing0.0000 ± 0.0000
SecondaryMaximum Plasma Concentration (Cmax) of Marstacimab

Maximum plasma concentration of marstacimab after participants received a single SC injection of marstacimab 300 mg.

Time frame:
Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of Marstacimab
ng/mLPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Maximum Plasma Concentration (Cmax) of Marstacimab15610 ± 35
SecondaryTime for Cmax (Tmax) of Marstacimab

Time for Cmax of marstacimab after participants received a single SC injection of marstacimab 300 mg.

Time frame:
Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Reported as:
Median · hour
Time for Cmax (Tmax) of Marstacimab
hourPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Time for Cmax (Tmax) of Marstacimab73.15 (71.9 to 167)
SecondaryArea Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Marstacimab

Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration of marstacimab after participants received a single SC injection of marstacimab 300 mg.

Time frame:
Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Reported as:
Geometric mean · nanogram * hour/milliliter (ng*hr/mL)
Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Marstacimab
nanogram * hour/milliliter (ng*hr/mL)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Marstacimab2917000 ± 60
SecondaryArea Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinity (AUCinf) of Marstacimab

Area under the concentration time curve from time zero to infinity of marstacimab after participants received a single SC injection of marstacimab 300 mg.

Time frame:
Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinity (AUCinf) of Marstacimab
ng*hr/mLPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinity (AUCinf) of Marstacimab4549000 ± 7
SecondaryTerminal Half-Life (t1/2) of Marstacimab

Terminal half life (t1/2) of marstacimab after participants received a single SC injection of marstacimab 300 mg. t1/2 is defined as the time for plasma concentration to decrease by one half.

Time frame:
Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Reported as:
Mean · hour
Terminal Half-Life (t1/2) of Marstacimab
hourPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Terminal Half-Life (t1/2) of Marstacimab90.48 ± 26.025
SecondaryApparent Volume of Distribution (Vz/F) of Marstacimab

Apparent volume of distribution of marstacimab after participants received a single SC injection of marstacimab 300 mg. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was influenced by the fraction absorbed. Vz/F was calculated as dose/AUCinf. AUCinf = area under the concentration time curve from time zero to infinity.

Time frame:
Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution (Vz/F) of Marstacimab
LiterPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Apparent Volume of Distribution (Vz/F) of Marstacimab8.305 ± 29
SecondaryApparent Clearance (CL/F) of Marstacimab

Apparent clearance (CL/F) of marstacimab after participants received a single SC injection of marstacimab 300 mg. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as Dose/ (AUCinf\*kel). AUCinf = area under the concentration time curve from time zero to infinity. kel = terminal phase rate constant calculated by a linear regression of the log linear concentration time curve.

Time frame:
Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Reported as:
Geometric mean · Liter per hour
Apparent Clearance (CL/F) of Marstacimab
Liter per hourPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Apparent Clearance (CL/F) of Marstacimab0.06595 ± 7
SecondaryMaximum Increase From Baseline for Tissue Factor Pathway Inhibitor (TFPI), Day 1 up to Day 28

TFPI is a protease inhibitor, which acts as an antagonist of the extrinsic coagulation pathway via inhibition of tissue factor-activated coagulation factor VII (FVIIa) and activated factor X (FXa). Plasma total TFPI levels were measured to reflect target binding with marstacimab. TFPI in results represented total TFPI.

Time frame:
Day 1 to Day 28
Reported as:
Mean · ng/mL
Maximum Increase From Baseline for Tissue Factor Pathway Inhibitor (TFPI), Day 1 up to Day 28
ng/mLPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Maximum Increase From Baseline for Tissue Factor Pathway Inhibitor (TFPI), Day 1 up to Day 2879.50 ± 36.374
SecondaryArea Under the Curve (AUC) of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for TFPI

A change from baseline-time profile was established based on changes from baseline in TFPI at specific time points. Area under the TFPI change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure. TFPI represented total TFPI.

Time frame:
Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Reported as:
Mean · ng*hr/mL
Area Under the Curve (AUC) of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for TFPI
ng*hr/mLPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
AUC of change from baseline values Days 1-7 for TFPI5730.07 ± 2891.283
AUC of change from baseline values Days 1-14 for TFPI15425.73 ± 9469.364
AUC of change from baseline values Days 1-28 for TFPI15526.33 ± 14100.382
SecondaryMaximum Increase From Baseline for Prothrombin Fragments 1+2 (PF 1+2), Day 1 up to Day 28

PF1+2 is an in vivo endpoint reflective of coagulation pathway activation. Maximum increase from baseline for PF 1+2 was provided.

Time frame:
Day 1 to Day 28
Reported as:
Mean · picomole per liter (pmol/L)
Maximum Increase From Baseline for Prothrombin Fragments 1+2 (PF 1+2), Day 1 up to Day 28
picomole per liter (pmol/L)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Maximum Increase From Baseline for Prothrombin Fragments 1+2 (PF 1+2), Day 1 up to Day 28531.9 ± 126.91
SecondaryAUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for PF 1+2

A change from baseline-time profile was established based on changes from baseline in PF 1+2 at specific time points. Area under the PF 1+2 change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.

Time frame:
Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Reported as:
Mean · picomole * hour/liter (pmol*hr/L)
AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for PF 1+2
picomole * hour/liter (pmol*hr/L)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
AUC of change from baseline values Days 1-7 for PF 1+256871.2823 ± 17578.69955
AUC of change from baseline values Days 1-14 for PF 1+2116439.2948 ± 38634.76646
AUC of change from baseline values Days 1-28 for PF 1+2144733.7020 ± 49783.67150
SecondaryMaximum Increase From Baseline for D-Dimer, Day 1 up to Day 28

D-dimer is an in vivo endpoint reflective of coagulation pathway activation. Maximum increase from baseline for D-Dimer is provided.

Time frame:
Day 1 to Day 28
Reported as:
Mean · microgram per milliliter (µg/mL)
Maximum Increase From Baseline for D-Dimer, Day 1 up to Day 28
microgram per milliliter (µg/mL)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Maximum Increase From Baseline for D-Dimer, Day 1 up to Day 280.463 ± 0.2881
SecondaryAUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for D-Dimer

A change from baseline-time profile was established based on changes from baseline in D-dimer at specific time points. Area under the D-dimer change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.

Time frame:
Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Reported as:
Mean · microgram * hour/milliliter (µg*hr/mL)
AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for D-Dimer
microgram * hour/milliliter (µg*hr/mL)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
AUC of change from baseline values Days 1-7 for D-dimer46.245 ± 29.3806
AUC of change from baseline values Days 1-14 for D-dimer110.855 ± 71.0567
AUC of change from baseline values Days 1-28 for D-dimer176.463 ± 153.1565
SecondaryMaximum Decrease From Baseline for Dilute Prothrombin Time (dPT), Day 1 up to Day 28

The dilute prothrombin time (dPT) is an ex vivo endpoint reflective of coagulation pathway activation. Maximum decrease from baseline for dPT is provided.

Time frame:
Day 1 to Day 28
Reported as:
Mean · second
Maximum Decrease From Baseline for Dilute Prothrombin Time (dPT), Day 1 up to Day 28
secondPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Maximum Decrease From Baseline for Dilute Prothrombin Time (dPT), Day 1 up to Day 28-19.62 ± 13.079
SecondaryAUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for dPT

A change from baseline-time profile was established based on changes from baseline in dPT at specific time points. Area under the dPT change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.

Time frame:
Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Reported as:
Mean · second * hour (sec*hr)
AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for dPT
second * hour (sec*hr)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
AUC of change from baseline values Days 1-7 for dPT-1910.10 ± 1800.853
AUC of change from baseline values Days 1-14 for dPT-4079.87 ± 4094.644
AUC of change from baseline values Days 1-28 for dPT-6792.18 ± 7068.384
SecondaryMaximum Decrease From Baseline for Thrombin Generation Assay (TGA) Lag Time, Day 1 up to Day 28

TGA lag time is an ex vivo endpoint reflective of coagulation pathway activation. Maximum decrease from baseline for TGA Lag Time is provided.

Time frame:
Day 1 to Day 28
Reported as:
Mean · minute
Maximum Decrease From Baseline for Thrombin Generation Assay (TGA) Lag Time, Day 1 up to Day 28
minutePF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Maximum Decrease From Baseline for Thrombin Generation Assay (TGA) Lag Time, Day 1 up to Day 28-0.92 ± 0.279
SecondaryAUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for TGA Lag Time

A change from baseline-time profile was established based on changes from baseline in TGA lag time at specific time points. Area under the TGA lag time change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.

Time frame:
Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Reported as:
Mean · minute * hour (min*hr)
AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for TGA Lag Time
minute * hour (min*hr)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
AUC of change from baseline values Days 1-7 for TGA lag time-95.10 ± 37.787
AUC of change from baseline values Days 1-14 for TGA lag time-188.08 ± 81.227
AUC of change from baseline values Days 1-28 for TGA lag time-174.70 ± 234.641
SecondaryMaximum Increase From Baseline for TGA Peak, Day 1 up to Day 28

TGA peak is an ex vivo endpoint reflective of coagulation pathway activation. Maximum increase from baseline for TGA Peak is provided.

Time frame:
Day 1 to Day 28
Reported as:
Mean · nanomole (nmol)
Maximum Increase From Baseline for TGA Peak, Day 1 up to Day 28
nanomole (nmol)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Maximum Increase From Baseline for TGA Peak, Day 1 up to Day 28105.83 ± 13.124
SecondaryAUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for TGA Peak

A change from baseline-time profile was established based on changes from baseline in TGA peak at specific time points. Area under the TGA peak change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.

Time frame:
Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Reported as:
Mean · nanomole * hour (nmol*hr)
AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for TGA Peak
nanomole * hour (nmol*hr)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
AUC of change from baseline values Days 1-7 for TGA peak10584.58 ± 3169.434
AUC of change from baseline values Days 1-14 for TGA peak20276.98 ± 5557.219
AUC of change from baseline values Days 1-28 for TGA peak28016.08 ± 9062.199
SecondaryMaximum Increase From Baseline for TGA Endogenous Thrombin Potential (EGTP), Day 1 up to Day 28

TGA EGTP is an ex vivo endpoint reflective of coagulation pathway activation. Maximum increase from baseline for TGA Endogenous Thrombin Potential is provided.

Time frame:
Day 1 to Day 28
Reported as:
Mean · nanomole * minute (nmol*min)
Maximum Increase From Baseline for TGA Endogenous Thrombin Potential (EGTP), Day 1 up to Day 28
nanomole * minute (nmol*min)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Maximum Increase From Baseline for TGA Endogenous Thrombin Potential (EGTP), Day 1 up to Day 281093.7 ± 332.76
SecondaryAUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for TGA EGTP

A change from baseline-time profile was established based on changes from baseline in TGA EGTP at specific time points. Area under the TGA EGTP change from baseline-time profile from time zero (Day 1) to Day 7, from time zero to Day 14 and from time zero to Day 28 are presented in this outcome measure.

Time frame:
Pre-dose, and 1 hour, 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, and approximately 144 hours, 312 hours, 480 hours and 648 hours post Day 1 dosing
Reported as:
Mean · nanomole * minute * hour (nmol*min*hr)
AUC of Change From Baseline Values (Days 1-7, Days 1-14, Days 1-28) for TGA EGTP
nanomole * minute * hour (nmol*min*hr)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
AUC of change from baseline values Days 1-7 for TGA EGTP123700.0 ± 35312.50
AUC of change from baseline values Days 1-14 for TGA EGTP238797.8 ± 47387.58
AUC of change from baseline values Days 1-28 for TGA EGTP332461.2 ± 69573.95
SecondaryNumber of Participants With Anti-Drug Antibody (ADA) Against Marstacimab

Summary of ADA incidence by visit is presented. ADA positive was defined as titer \>=1.54.

Time frame:
Day 1 pre-dose (-2 hours to -5 min prior to dosing); Day 14; Day 21; Day 28
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibody (ADA) Against Marstacimab
ParticipantsPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Day 10
Day 140
Day 211
Day 281
SecondaryNumber of Participants With Neutralizing Antibody (NAb) Against Marstacimab

Summary of NAb incidence by visit is presented. NAb positive was defined as titer \>=1.08. ADA-positive participants (defined as titer \>=1.54) were analyzed for NAb.

Time frame:
Day 1 pre-dose (-2 hours to -5 min prior to dosing); Day 14; Day 21; Day 28
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing Antibody (NAb) Against Marstacimab
ParticipantsPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Day 10
Day 140
Day 210
Day 280

Adverse events

Collected over Baseline (Day 1) to Day 42. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose0/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent other events
Most frequent other events
EventPF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Upper respiratory tract infectionInfections and infestations1/6

Baseline characteristics

Baseline analysis population included all participants enrolled in the study who received the study intervention.

Age, Continuous
Age, Continuous(years)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Median31.5 (27 to 34)
Age, Customized
Age, Customized(Participants)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
<18 years0
18-64 years6
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Female0
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
Chinese6
Other (Not Chinese)0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PF-06741086 (Marstacimab) 300 mg Subcutaneous (SC) Single Dose
White0
Black or African American0
Asian6
American Indian or Alaska Native0
Native Hawaiian or Other Pacific Islander0
Not Reported0
08

Study locations

1 site
  • Institute of Hematology, Chinese Academy of Medical Sciences
    Tianjin, Tianjin 300020, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Aug 2021, 3 months.

Results were first posted in Jul 2023, 1 year 10 months after primary completion.

Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 3 months is below that.

Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2021
First posted
May 7, 2021
StartActual
Apr 16, 2021
Primary completionActual
Aug 10, 2021
CompletionActual
Aug 10, 2021
Results first posted
Jul 7, 2023
Last update
Jul 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04878731
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 7, 2021
Start date
Apr 16, 2021
Primary completion
Aug 10, 2021
Completion
Aug 10, 2021
Results posted
Jul 7, 2023
Last update
Jul 7, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Marstacimab

Start the discussion